Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: METASTATIC BREAST CANCER, . Treffer: 50

2023

Suppan, C; Balic, M Current standards and future outlooks in metastatic Her2-positive breast cancer
BREAST CARE. 2023; Doi: 10.1159/000528756 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2022

Suppan, C; Graf, R; Jahn, S; Zhou, Q; Klocker, EV; Bartsch, R; Terbuch, A; Kashofer, K; Regitnig, P; Lindenmann, J; Posch, F; Gerritsmann, H; Jost, PJ; Heitzer, E; Dandachi, N; Balic, M Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients.
Br J Cancer. 2022; 126(3):456-463 Doi: 10.1038/s41416-021-01601-9 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2021

Aftimos, P; Oliveira, M; Irrthum, A; Fumagalli, D; Sotiriou, C; Gal-Yam, EN; Robson, ME; Ndozeng, J; Di, Leo, A; Ciruelos, EM; de, Azambuja, E; Viale, G; Scheepers, ED; Curigliano, G; Bliss, JM; Reis-Filho, JS; Colleoni, M; Balic, M; Cardoso, F; Albanell, J; Duhem, C; Marreaud, S; Romagnoli, D; Rojas, B; Gombos, A; Wildiers, H; Guerrero-Zotano, A; Hall, P; Bonetti, A; Larsson, KF; Degiorgis, M; Khodaverdi, S; Greil, R; Sverrisdóttir, Á; Paoli, M; Seyll, E; Loibl, S; Linderholm, B; Zoppoli, G; Davidson, NE; Johannsson, OT; Bedard, PL; Loi, S; Knox, S; Cameron, DA; Harbeck, N; Montoya, ML; Brandão, M; Vingiani, A; Caballero, C; Hilbers, FS; Yates, LR; Benelli, M; Venet, D; Piccart, MJ Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative.
Cancer Discov. 2021; 11(11): 2796-2811. Doi: 10.1158/2159-8290.CD-20-1647 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Dandachi, N; Posch, F; Graf, R; Suppan, C; Klocker, EV; Müller, HD; Lindenmann, J; Terbuch, A; Heitzer, E; Balic, M Longitudinal tumor fraction trajectories predict risk of progression in metastatic HR+ breast cancer patients undergoing CDK4/6 treatment.
Mol Oncol. 2021; 15(9):2390-2400 Doi: 10.1002/1878-0261.12870 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Gampenrieder, SP; Rinnerthaler, G; Tinchon, C; Petzer, A; Balic, M; Heibl, S; Schmitt, C; Zabernigg, AF; Egle, D; Sandholzer, M; Singer, CF; Roitner, F; Hager, C; Andel, J; Hubalek, M; Knauer, M; Greil, R Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.
BREAST CANCER RES. 2021; 23(1): 112 Doi: 10.1186/s13058-021-01492-x [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Hubalek, M; Petru, E; Sandholzer, M; Andel, J; Balic, M; Melchardt, T; Hauser-Kronberger, C; Schmitt, CA; Ulmer, H; Greil, R Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6).
Ther Adv Med Oncol. 2021; 13: 17588359211042301 Doi: 10.1177/17588359211042301 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Suppan, C Post San Antonio update-my top three abstracts!
MEMO-MAG EUR MED ONC. 2021; Doi: 10.1007/s12254-021-00718-0
Web of Science FullText FullText_MUG

 

2020

Bourrier, C; Pierga, JY; Xuereb, L; Salaun, H; Proudhon, C; Speicher, MR; Belic, J; Heitzer, E; Lockhart, BP; Guigal-Stephan, N Shallow Whole-Genome Sequencing from Plasma Identifies FGFR1 Amplified Breast Cancers and Predicts Overall Survival.
Cancers (Basel). 2020; 12(6): Doi: 10.3390/cancers12061481 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Steger, GG; Egle, D; Bartsch, R; Pfeiler, G; Petru, E; Greil, R; Helfgott, R; Marth, C; Öhler, L; Hubalek, M; Lang, A; Tinchon, C; Haslbauer, F; Redl, A; Hock, K; Hennebelle, M; Mraz, B; Gnant, M Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.
Breast. 2020; 50:64-70 Doi: 10.1016/j.breast.2020.01.035 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2019

Cazzaniga, ME; Munzone, E; Bocci, G; Afonso, N; Gomez, P; Langkjer, S; Petru, E; Pivot, X; Sánchez Rovira, P; Wysocki, P; Torri, V Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project.
ADV THER. 2019; 36(2): 381-406. Doi: 10.1007/s12325-018-0844-4
Web of Science PubMed FullText FullText_MUG

 

Suppan, C; Brcic, I; Tiran, V; Mueller, HD; Posch, F; Auer, M; Ercan, E; Ulz, P; Cote, RJ; Datar, RH; Dandachi, N; Heitzer, E; Balic, M Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment.
Cancers (Basel). 2019; 11(8): Doi: 10.3390/cancers11081171 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2018

de Wit, S; Manicone, M; Rossi, E; Lampignano, R; Yang, L; Zill, B; Rengel-Puertas, A; Ouhlen, M; Crespo, M; Berghuis, AMS; Andree, KC; Vidotto, R; Trapp, EK; Tzschaschel, M; Colomba, E; Fowler, G; Flohr, P; Rescigno, P; Fontes, MS; Zamarchi, R; Fehm, T; Neubauer, H; Rack, B; Alunni-Fabbroni, M; Farace, F; De Bono, J; IJzerman, MJ; Terstappen, LWMM EpCAMhigh and EpCAMlow circulating tumor cells in metastatic prostate and breast cancer patients.
Oncotarget. 2018; 9(86):35705-35716 Doi: 10.18632/oncotarget.26298 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

Stanzer, S; Andritsch, E; Zloklikovits, S; Ladinek, V; Farkas, C; Augustin, T; Obermayer-Pietsch, B; Samonigg, H; Bauernhofer, T A Pilot Randomized Trial Assessing the Effect of a Psychoeducational Intervention on Psychoneuroimmunological Parameters Among Patients With Nonmetastatic Breast Cancer.
Psychosom Med. 2018; 81(2):165-175 Doi: 10.1097/PSY.0000000000000656
Web of Science PubMed FullText FullText_MUG

 

Wöckel, A; Festl, J; Stüber, T; Brust, K; Krockenberger, M; Heuschmann, PU; Jírů-Hillmann, S; Albert, US; Budach, W; Follmann, M; Janni, W; Kopp, I; Kreienberg, R; Kühn, T; Langer, T; Nothacker, M; Scharl, A; Schreer, I; Link, H; Engel, J; Fehm, T; Weis, J; Welt, A; Steckelberg, A; Feyer, P; König, K; Hahne, A; Baumgartner, T; Kreipe, HH; Knoefel, WT; Denkinger, M; Brucker, S; Lüftner, D; Kubisch, C; Gerlach, C; Lebeau, A; Siedentopf, F; Petersen, C; Bartsch, HH; Schulz-Wendtland, R; Hahn, M; Hanf, V; Müller-Schimpfle, M; Henscher, U; Roncarati, R; Katalinic, A; Heitmann, C; Honegger, C; Paradies, K; Bjelic-Radisic, V; Degenhardt, F; Wenz, F; Rick, O; Hölzel, D; Zaiss, M; Kemper, G; Budach, V; Denkert, C; Gerber, B; Tesch, H; Hirsmüller, S; Sinn, HP; Dunst, J; Münstedt, K; Bick, U; Fallenberg, E; Tholen, R; Hung, R; Baumann, F; Beckmann, MW; Blohmer, J; Fasching, P; Lux, MP; Harbeck, N; Hadji, P; Hauner, H; Heywang-Köbrunner, S; Huober, J; Hübner, J; Jackisch, C; Loibl, S; Lück, HJ; von Minckwitz, G; Möbus, V; Müller, V; Nöthlings, U; Schmidt, M; Schmutzler, R; Schneeweiss, A; Schütz, F; Stickeler, E; Thomssen, C; Untch, M; Wesselmann, S; Bücker, A; Buck, A; Stangl, S Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer.
Geburtshilfe Frauenheilkd. 2018; 78(11):1056-1088 Doi: 10.1055/a-0646-4630 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2017

Benezeder, T; Tiran, V; Treitler, AAN; Suppan, C; Rossmann, C; Stoeger, H; Cote, RJ; Datar, RH; Balic, M; Dandachi, N Multigene methylation analysis of enriched circulating tumor cells associates with poor progression-free survival in metastatic breast cancer patients.
Oncotarget. 2017; 8(54):92483-92496 Doi: 10.18632/oncotarget.21426 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Tiran, V; Stanzer, S; Heitzer, E; Meilinger, M; Rossmann, C; Lax, S; Tsybrovskyy, O; Dandachi, N; Balic, M Genetic profiling of putative breast cancer stem cells from malignant pleural effusions.
PLoS One. 2017; 12(4):e0175223-e0175223 Doi: 10.1371/journal.pone.0175223 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Trapp, EK; Majunke, L; Zill, B; Sommer, H; Andergassen, U; Koch, J; Harbeck, N; Mahner, S; Friedl, TWP; Janni, W; Rack, B; Alunni-Fabbroni, M LKB1 pro-oncogenic activity triggers cell survival in circulating tumor cells.
Mol Oncol. 2017; 11(11):1508-1526 Doi: 10.1002/1878-0261.12111 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2016

Schramm, A; Friedl, TW; Schochter, F; Scholz, C; de Gregorio, N; Huober, J; Rack, B; Trapp, E; Alunni-Fabbroni, M; Müller, V; Schneeweiss, A; Pantel, K; Meier-Stiegen, F; Hartkopf, A; Taran, FA; Wallwiener, D; Janni, W; Fehm, T Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
Arch Gynecol Obstet. 2016; 293(2):271-281 Doi: 10.1007/s00404-015-3879-7
Web of Science PubMed FullText FullText_MUG

 

2015

Didiasova, M; Zakrzewicz, D; Magdolen, V; Nagaraj, C; Bálint, Z; Rohde, M; Preissner, KT; Wygrecka, M STIM1/ORAI1-mediated Ca2+ Influx Regulates Enolase-1 Exteriorization.
J Biol Chem. 2015; 290(19):11983-11999 Doi: 10.1074/jbc.M114.598425 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Pircher, M; Mlineritsch, B; Fridrik, MA; Dittrich, C; Lang, A; Petru, E; Weltermann, A; Thaler, J; Hufnagl, C; Gampenrieder, SP; Rinnerthaler, G; Ressler, S; Ulmer, H; Greil, R Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
Anticancer Res. 2015; 35(1):517-521
Web of Science PubMed

 

2014

Heidary, M; Auer, M; Ulz, P; Heitzer, E; Petru, E; Gasch, C; Riethdorf, S; Mauermann, O; Lafer, I; Pristauz, G; Lax, S; Pantel, K; Geigl, JB; Speicher, MR The dynamic range of circulating tumor DNA in metastatic breast cancer.
Breast Cancer Res. 2014; 16(4):421-421 Doi: 10.1186/s13058-014-0421-y [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Krenn-Pilko, S; Langsenlehner, U; Thurner, EM; Stojakovic, T; Pichler, M; Gerger, A; Kapp, KS; Langsenlehner, T The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients.
Br J Cancer. 2014; 110(10):2524-2530 Doi: 10.1038/bjc.2014.163 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Peintinger, F Using molecular profiles to tailor treatment in breast cancer: are they ready for prime time?
Curr Opin Obstet Gynecol. 2014; 26(1):21-26 Doi: 10.1097/GCO.0000000000000041
Web of Science PubMed FullText FullText_MUG

 

Regierer, AC; Wolters, R; Ufen, MP; Weigel, A; Novopashenny, I; Köhne, CH; Samonigg, H; Eucker, J; Possinger, K; Wischnewsky, MB An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients.
Ann Oncol. 2014; 25(3):633-638 Doi: 10.1093/annonc/mdt539 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Rordorf, T; Hassan, AA; Azim, H; Alexandru, E; Er, O; Gokmen, E; Güral, Z; Mardiak, J; Minchev, V; Peintinger, F; Szendroi, M; Takac, I; Tesarova, P; Vorobiof, D; Vrbanec, D; Yildiz, R; Yücel, S; Zekri, J; Oyan, B; Central European Cooperative Oncology Group (CECOG); Swiss Group for Clinical Cancer Research (SAKK) Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup.
Breast. 2014; 23(5):511-525 Doi: 10.1016/j.breast.2014.05.023 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2013

Heitzer, E; Auer, M; Hoffmann, EM; Pichler, M; Gasch, C; Ulz, P; Lax, S; Waldispuehl-Geigl, J; Mauermann, O; Mohan, S; Pristauz, G; Lackner, C; Höfler, G; Eisner, F; Petru, E; Sill, H; Samonigg, H; Pantel, K; Riethdorf, S; Bauernhofer, T; Geigl, JB; Speicher, MR Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer.
Int J Cancer. 2013; 133(2):346-356 Doi: 10.1002/ijc.28030 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2012

Labonte, MJ; Wilson, PM; Yang, D; Zhang, W; Ladner, RD; Ning, Y; Gerger, A; Bohanes, PO; Benhaim, L; El-Khoueiry, R; El-Khoueiry, A; Lenz, HJ The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.
Ann Oncol. 2012; 23(6):1455-1464 Doi: 10.1093/annonc/mdr445 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2010

Idris, T; Krippl, P; Lang, U; Petru, E Long-Term Disease Control with Lapatinib and Capecitabine in a Heavily Pretreated Patient with ErbB2-Positive Metastatic Breast Cancer.
Breast Care (Basel). 2010; 5(5):335-337 Doi: 10.1159/000321394 (- Case Report) [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2009

Mlineritsch, B; Schabel-Moser, R; Andel, J; Fridrik, M; Moik, M; Mayer, P; Russ, G; Rass, C; Greil, R; Arbeitsgemeinschaft medikamentöse Tumortherapie Study Group Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.
Onkologie. 2009; 32(1-2):18-24 Doi: 10.1159/000180915
Web of Science PubMed FullText FullText_MUG

 

2008

Schmid, P; Kühnhardt, D; Kiewe, P; Lehenbauer-Dehm, S; Schippinger, W; Greil, R; Lange, W; Preiss, J; Niederle, N; Brossart, P; Freier, W; Kümmel, S; Van de Velde, H; Regierer, A; Possinger, K A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Ann Oncol. 2008; 19(5):871-876 Doi: 10.1093/annonc/mdm569 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2007

Zheng, S; Lin, H; Liu, JQ; Balic, M; Datar, R; Cote, RJ; Tai, YC Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells.
J Chromatogr A. 2007; 1162(2):154-161 Doi: 10.1016/j.chroma.2007.05.064
Web of Science PubMed FullText FullText_MUG

 

2006

Bjelic-Radisic, V; Stöger, H; Winter, R; Beham-Schmid, C; Petru, E Long-term control of bone marrow carcinosis and severe thrombocytopenia with standard-dose chemotherapy in a breast cancer patient: a case report.
Anticancer Res. 2006; 26(2B):1627-1630 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText Google Scholar

 

Schippinger, W; Regitnig, P; Dandachi, N; Wernecke, KD; Bauernhofer, T; Samonigg, H; Moinfar, F Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer.
Virchows Arch. 2006; 449(1):24-30 Doi: 10.1007/s00428-006-0213-6
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2005

Bauernhofer, T; Zenahlik, S; Hofmann, G; Balic, M; Resel, M; Pirchmoser, R; Regitnig, P; Ambros, P; Dandachi, N; Samonigg, H Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer.
Oncol Rep. 2005; 13(2):179-184
Web of Science PubMed FullText Google Scholar

 

Schmid, P; Schippinger, W; Nitsch, T; Huebner, G; Heilmann, V; Schultze, W; Hausmaninger, H; Wischnewsky, M; Possinger, K Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.
J Clin Oncol. 2005; 23(3):432-440 Doi: 10.1200/JCO.2005.06.072 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2004

Salvan, CV; Ulmer, JL; DeYoe, EA; Wascher, T; Mathews, VP; Lewis, JW; Prost, RW Visual object agnosia and pure word alexia: correlation of functional magnetic resonance imaging and lesion localization.
J Comput Assist Tomogr. 2004; 28(1):63-67 Doi: 10.1097/00004728-200401000-00010 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Schippinger, W; Regitnig, P; Bauernhofer, T; Ploner, F; Hofmann, G; Krippl, P; Wehrschütz, M; Lax, S; Carney, W; Neumann, R; Wernecke, KD; Samonigg, H The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.
ONCOL REP. 2004; 11(6): 1331-1336. Doi: 10.3892/or.11.6.1331
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2003

Denison, U; Baumann, J; Peters-Engl, C; Samonigg, H; Krippl, P; Lang, A; Obermair, A; Wagner, H; Sevelda, P Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy.
Breast Cancer Res Treat. 2003; 79(3):347-353 Doi: 10.1023/A:1024016508925
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Nieder, C; Jost, PJ; Grosu, AL; Peschel, C; Molls, M Report of a male patient with brain metastases from breast cancer.
Breast. 2003; 12(5):345-347 Doi: 10.1016/s0960-9776(03)00109-7 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Paridaens, R; Van Aelst, F; Georgoulias, V; Samonigg, H; Cocquyt, V; Zielinski, C; Hausmaninger, H; Willemse, P; Boudraa, Y; Wildiers, J; Ramazeilles, C; Azli, N A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer.
ANN ONCOL. 2003; 14(3): 433-440. Doi: 10.1093/annonc/mdg111 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2002

Heidemann, E; Stoeger, H; Souchon, R; Hirschmann, WD; Bodenstein, H; Oberhoff, C; Fischer, JT; Schulze, M; Clemens, M; Andreesen, R; Mahlke, M; König, M; Scharl, A; Fehnle, K; Kaufmann, M Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial.
Ann Oncol. 2002; 13(11):1717-1729 Doi: 10.1096/annonc/mdf306 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

1995

Hausmaninger, H; Lehnert, M; Steger, G; Sevelda, P; Tschurtschenthaler, G; Hehenwarter, W; Fridrik, M; Samonigg, H; Schiller, L; Manfreda, D Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer.
Eur J Cancer. 1995; 31A(13-14):2169-2173 Doi: 10.1016%2F0959-8049%2895%2900489-0
Web of Science PubMed FullText FullText_MUG Google Scholar

 

1990

Samonigg, H; Stöger, H; Bauernhofer, T; Schmid, M; Kasparek, AK; Kuss, I; Kaul, M; Heberle, U; Vieder, L; Dusleag, J Combination therapy of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose folinic acid in patients with advanced breast cancer: a phase I-II study (preliminary results).
Am J Clin Oncol. 1990; 13 Suppl 1(4):S44-S47 Doi: 10.1097/00000421-199012001-00010
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Scheithauer, W; Samonigg, H; Depisch, D; Schüller, J; Hausmaninger, H; Wiegele, J; Zielinsky, C; Stöger, H; Haider, K; Preis, P Pirarubicin (4'-o-tetrahydropyranil-adriamycin) for treatment of advanced breast cancer. A Clinical Phase II study.
Invest New Drugs. 1990; 8(2):207-210 Doi: 10.1007/BF00177262
Web of Science PubMed FullText FullText_MUG Google Scholar

 

1989

Hausmaninger, H; Lehnert, M; Steger, G; Sevelda, P; Michlmayr, G; Hehenwarter, W; Fridrik, M; Samonigg, H; Schiller, L; Manfreda, D Vindesine-epirubicin versus vindesine-mitoxantrone in metastatic breast cancer.
Onkologie. 1989; 12(5):225-229 Doi: 10.1159/000216651
Web of Science PubMed FullText FullText_MUG Google Scholar

 

1986

Lehnert, M; Biffl, G; Wascher, H; Jordis-Lohausen, K; Wählby, S A preliminary analysis of combination therapy with vincristine, adriamycin, and prednimustine (VAP) in advanced breast cancer: a phase II study.
Semin Oncol. 1986; 13(1 Suppl 1):32-34
Web of Science PubMed

 

1985

Samonigg, H Value of hormone therapy in metastasizing breast cancer
WIEN MED WOCHENSCHR. 1985; 135(23-24): 602-607.
Web of Science PubMed

 

Wascher, H Chemotherapy of metastasizing breast cancer
Wien Med Wochenschr. 1985; 135(23-24):590-594
Web of Science PubMed

 

1984

Beaufort, F; Gölles, M Calcitonin in bone-metastasizing breast carcinoma. Results of a pilot study
Onkologie. 1984; 7(3):137-140 Doi: 10.1159/000215425
Web of Science PubMed FullText FullText_MUG

 

1982

Beaufort, F Remission maintenance with cytostatic long-term therapy in metastatic breast cancer
Onkologie. 1982; 5 Suppl(4):52-54
Web of Science PubMed

 

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum